Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset
Standard
Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset. / Chari, Ajai; Samur, Mehmet Kemal; Martinez-Lopez, Joaquin; Cook, Gordon; Biran, Noa; Yong, Kwee L; Hungria, Vania Tietsche de Moraes; Engelhardt, Monika; Gay, Francesca; Garcia-Feria, Ana; Oliva, Stefania; Oostvogels, Rimke; Gozzetti, Alessandro; Rosenbaum, Cara A; Kumar, Shaji K; Stadtmauer, Edward; Einsele, Hermann; Beksac, Meral; Weisel, Katja C; Anderson, Kenneth C; Mateos, Maria-Victoria; Moreau, Philippe; San Miguel, Jesús; Munshi, Nikhil C; Avet-Loiseau, Hervé.
in: BLOOD, 06.11.2020.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset
AU - Chari, Ajai
AU - Samur, Mehmet Kemal
AU - Martinez-Lopez, Joaquin
AU - Cook, Gordon
AU - Biran, Noa
AU - Yong, Kwee L
AU - Hungria, Vania Tietsche de Moraes
AU - Engelhardt, Monika
AU - Gay, Francesca
AU - Garcia-Feria, Ana
AU - Oliva, Stefania
AU - Oostvogels, Rimke
AU - Gozzetti, Alessandro
AU - Rosenbaum, Cara A
AU - Kumar, Shaji K
AU - Stadtmauer, Edward
AU - Einsele, Hermann
AU - Beksac, Meral
AU - Weisel, Katja C
AU - Anderson, Kenneth C
AU - Mateos, Maria-Victoria
AU - Moreau, Philippe
AU - San Miguel, Jesús
AU - Munshi, Nikhil C
AU - Avet-Loiseau, Hervé
N1 - Copyright © 2020 American Society of Hematology.
PY - 2020/11/6
Y1 - 2020/11/6
N2 - The primary cause of morbidity and mortality in patients with multiple myeloma(MM) is an infection. Therefore there is great concern about the susceptibility to the outcome of COVID-19 infected patients with MM. This retrospective study describes the baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International Myeloma Society to understand the initial challenges faced by myeloma patients during COVID-19 pandemic. Analysis were performed for hospitalized MM patients. Among hospitalized patinets, the median age was 69 years, and nearly all patients(96%) had MM. Approximately 36% were recently diagnosed(2019-2020), and 54% of patients were receiving first-line therapy. Thirty-three percent of patients have died, with significant geographic variability, ranging from 27% to 57% of hospitalized patients. Univariate analysis identified age, ISS3, high-risk disease, renal disease, suboptimal myeloma control(active or progressive disease), and one or more comorbidities as risk factors for higher rates of death. Neither history of transplant, including within a year of COVID-19 diagnosis, nor other anti-MM treatments were associated with outcomes. Multivariate analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained independent predictors of adverse outcome with COVID-19 infection. The management of MM in the era of COVID-19 requires careful consideration of patient and disease-related factors to decrease the risk of acquiring COVID-19 infection, while not compromising disease control through appropriate MM treatment. This study provides initial data to develop recommendations for the management of MM patients with COVID-19 infection.
AB - The primary cause of morbidity and mortality in patients with multiple myeloma(MM) is an infection. Therefore there is great concern about the susceptibility to the outcome of COVID-19 infected patients with MM. This retrospective study describes the baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International Myeloma Society to understand the initial challenges faced by myeloma patients during COVID-19 pandemic. Analysis were performed for hospitalized MM patients. Among hospitalized patinets, the median age was 69 years, and nearly all patients(96%) had MM. Approximately 36% were recently diagnosed(2019-2020), and 54% of patients were receiving first-line therapy. Thirty-three percent of patients have died, with significant geographic variability, ranging from 27% to 57% of hospitalized patients. Univariate analysis identified age, ISS3, high-risk disease, renal disease, suboptimal myeloma control(active or progressive disease), and one or more comorbidities as risk factors for higher rates of death. Neither history of transplant, including within a year of COVID-19 diagnosis, nor other anti-MM treatments were associated with outcomes. Multivariate analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained independent predictors of adverse outcome with COVID-19 infection. The management of MM in the era of COVID-19 requires careful consideration of patient and disease-related factors to decrease the risk of acquiring COVID-19 infection, while not compromising disease control through appropriate MM treatment. This study provides initial data to develop recommendations for the management of MM patients with COVID-19 infection.
U2 - 10.1182/blood.2020008150
DO - 10.1182/blood.2020008150
M3 - SCORING: Journal article
C2 - 33156904
JO - BLOOD
JF - BLOOD
SN - 0006-4971
ER -